Statistics from Altmetric.com
We recently published in your journal a 3-year multicentre prospective cohort study demonstrating the usefulness of an epigenetic cancer risk marker for gastric metachronous cancers.1 This study achieved the first proof of concept of epigenetic cancer risk diagnosis in any type of cancer but, due to the short follow-up period, a relatively small number of events were observed, resulting in a marginally significant difference (p=0.042). It was anticipated that a longer follow-up could lead to a clearer difference and HR with a smaller 95% CI. We now report the 5-year follow-up data, which show highly significant results.
Among the 826 enrolled patients, 795 patients received annual follow-ups by endoscopy for a median period of 5.46 years (IQR: 3.95–6.09). By the end, 133 patients had developed a metachronous gastric cancer. Among them, 116 patients developed a metachronous gastric cancer detected 1 year after the enrolment (authentic metachronous cancer).
Statistical analyses were conducted in the same manner as previously described.1 Briefly, all the patients were categorised into quartiles (Q1: lowest to Q4: highest) according to the methylation levels of each of three genes (miR-124a-3, EMX1 and NKX6-1). Cumulative incidences of metachronous gastric cancers were compared by a log-rank test, and HRs and 95% CIs were assessed by univariate and multivariate analyses by adjusting known risk factors and possible confounding factors, using a Cox proportional hazard regression model.
The univariate and multivariate analyses showed that Q4 (highest) of each of the three genes had significantly higher HRs than Q1 (lowest), using all and authentic metachronous gastric cancers (p<0.005) (table 1). Especially, the multivariate-adjusted HR of Q4 for miR-124a-3 was 3.0 (95% CI 1.58 to 5.72, p=0.0017).
The Kaplan-Meier curves showed the cumulative incidences of the metachronous gastric cancers for quartiles (Q1–Q4) of methylation levels for each of the three genes (figure 1). For each gene, Q4 had a higher incidence of metachronous gastric cancer than Q1, with a p value of <0.001 by the log-rank test.
These final results based on the 5-year follow-up convincingly endorsed the proof of concept of epigenetic cancer risk diagnosis with sufficiently small p values, and provided a rationale that epigenetic markers can be used for cancer risk diagnosis. All the participants of this study once had a gastric cancer and thus originally carried a high risk of metachronous gastric cancer, as observed in Q1 (figure 1). Therefore, cancer risk stratification in this cohort was considered to be very difficult, but has been achieved. At the same time, the high risk inherent in the cohort will not allow changing the current clinical practice with annual endoscopic surveillance.
On the other hand, for asymptomatic Helicobacter pylori-infected individuals without a cancerous lesion, cancer risk stratification after their H. pylori eradication has been highly demanded because it can lead to optimisation of cancer surveillance based on an individual's risk. In order to establish precision medicine in this population, we have launched a new large-scale multicentre prospective cohort study (UMIN000016894) to predict the risk of primary gastric cancer in healthy individuals after H. pylori eradication.
The strong influence of methylation accumulation on gastric cancer risk was considered to be due to the major contribution of aberrant DNA methylation induced by H. pylori infection in gastric epithelial cells to gastric carcinogenesis, along with mutations produced by activation-induced cytidine deaminase.2 The relatively small number of driver mutations after comprehensive mutation analyses3 ,4 also supports the importance of methylation accumulation in gastric carcinogenesis.
Contributors Study concept: TU, TN and MF. Patients' follow-up and data collection: TN, NY, TM, CY, IO, TY, MF and TG. Experiments: KA, TA and SN. Data analysis: TS. Letter concept: KA, TU and MM. Drafting of the manuscript: TU and MM.
Funding This research was supported by the National Cancer Center Research and Development Fund (H26-A-15), Japan, and by the fund (16ck0106023h0003 to TU) for the Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development.
Competing interests None.
Patient consent Obtained.
Ethics approval The study was approved by the institutional review board at each hospital.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.